Research programme: CYC103 cyclin binding groove inhibitors - Cyclacel Pharmaceuticals
Alternative Names: CBG inhibitors; CYC103; CYC103 cell cycle peptidomimetics research programme - CyclacelLatest Information Update: 18 May 2011
At a glance
- Originator Cyclacel Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin-dependent kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Cancer
Most Recent Events
- 22 Jan 2008 This programme is still in active development
- 28 Mar 2006 Xcyte Therapies has merged with Cyclacel to form Cyclacel Pharmaceuticals
- 20 May 2005 This programme is still in active development